This experiment investigates how Apolipoprotein E4 (ApoE4) confers increased AD risk at the cellular level. ApoE4 is the strongest genetic risk factor for late-onset AD, with one copy increasing risk ~3x and two copies ~12x. The mechanism by which ApoE4 increases AD risk remains incompletely understood.
AD Gap #17: How does ApoE4 confer risk at the cellular level?
What are the cellular mechanisms by which ApoE4 promotes Aβ aggregation, neuroinflammation, and neurodegeneration, and can these be therapeutically targeted?
ApoE4 promotes AD pathogenesis through multiple mechanisms: enhanced Aβ binding and aggregation seeding, impaired Aβ clearance across the BBB, gain of neurotoxic lipoproteins, and amplified neuroinflammation via microglial dysregulation. Targeting these mechanisms will reduce AD risk in ApoE4 carriers.
Phase 1: ApoE4-Aβ Interaction Mapping
Phase 2: Cellular Mechanisms
Phase 3: In Vivo Validation
Phase 4: Therapeutic Targeting
| Factor | Rating | Notes |
|---|---|---|
| Technical feasibility | 8/10 | iPSC and mouse models well-established; ApoE4-KI mice available |
| Cost efficiency | 7/10 | Standard assays; gene therapy adds cost |
| Timeline | 18 months | Phases 1-2 (6 mo) + in vivo (9 mo) + therapy (6 mo) |
| Cross-disease value | 8/10 | Relevance to other ApoE-associated conditions |
| Component | Cost (USD) |
|---|---|
| Personnel (3 FTE × 18 mo) | $450,000 |
| iPSC differentiation and characterization | $120,000 |
| ApoE4-KI mice (200) | $80,000 |
| RNA-seq and lipidomics | $100,000 |
| PET imaging | $60,000 |
| ApoE4 correctors | $40,000 |
| Total | $850,000 |
Total Score: 75 (Rank 68)
| Dimension | Score |
|---|---|
| Mechanistic Impact | 9 |
| Cure Proximity | 7 |
| Feasibility | 7 |
| Cost Efficiency | 7 |
| Timeline | 6 |
| Cross-Disease Value | 8 |
| Biomarker Enablement | 6 |
| Combinability | 7 |
| De-risking Value | 8 |
| Novelty | 6 |